ProQR (PRQR) Reports First Patient Dosing in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
Tweet Send to a Friend
ProQR Therapeutics N.V. (NASDAQ: PRQR) today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for QR-421a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
